Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed <i>rpoB</i> Mutations and Discordant Susceptibility Phenotypes.

Wang, Wei; Liu, Rongmei; Yao, Cong; Huo, Fengmin; Shang, Yuanyuan; Zhang, Xuxia; Wang, Yufeng; Xue, Zhongtan; Ma, Liping; Pang, Yu

Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed rpoB Mutations and Discordant Susceptibility Phenotypes.

Wang, Wei; Liu, Rongmei; Yao, Cong; Huo, Fengmin; Shang, Yuanyuan; Zhang, Xuxia; Wang, Yufeng; Xue, Zhongtan; Ma, Liping; Pang, Yu.

Afiliação

Wang W; Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Liu R; Department of Tuberculosis, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Yao C; Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Huo F; National Tuberculosis Clinical Laboratory, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Shang Y; Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Zhang X; Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Wang Y; Innovation Alliance on Tuberculosis Diagnosis and Treatment, Beijing, People's Republic of China.
Xue Z; Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Ma L; Department of Tuberculosis, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Pang Y; Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.

Microbiol Spectr ; 10(1): e0208721, 2022 02 23.

Article em En | MEDLINE | ID: mdl-35107324

Assuntos

Proteínas de Bactérias/genética; RNA Polimerases Dirigidas por DNA/genética; Mutação; Mycobacterium tuberculosis/efeitos dos fármacos; Mycobacterium tuberculosis/genética; Rifampina/farmacologia; Antituberculosos/farmacologia; Proteínas de Bactérias/metabolismo; RNA Polimerases Dirigidas por DNA/metabolismo; Genótipo; Humanos; Testes de Sensibilidade Microbiana; Mycobacterium tuberculosis/isolamento & purificação; Fenótipo; Análise de Sequência de DNA; Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico; Tuberculose Resistente a Múltiplos Medicamentos/genética

Palavras-chave

Mycobacterium tuberculosis; mutations; rifampicin; rpoB; susceptibility

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Rifampina / Proteínas de Bactérias / RNA Polimerases Dirigidas por DNA / Mutação / Mycobacterium tuberculosis Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google